Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 20, Issue 12, Pages 3069-3077Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v20.i12.3069
Keywords
Cirrhosis; Hepatocellular carcinoma; Mortality; Embolization; Transarterial chemoembolization; Transarterial embolization; Prognosis
Categories
Ask authors/readers for more resources
Transarterial chemoembolization (TACE) is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth. Despite its widespread use, TACE remains an unstandardized procedure, with variation in type and size of embolizing particles, type and dose of chemotherapy and interval between therapies. Existing evidence from randomized controlled trials suggest that bland transarterial embolization (TAE) has the same efficacy with TACE. In the current article, we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available